Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment

被引:23
作者
Bonnekoh, B.
Pommer, A. J.
Boeckelmann, R.
Hofmeister, H.
Philipsen, L.
Gollnick, H.
机构
[1] Univ Leicester, Otto Von Guericke, Clin Dermatol & Venereol, DE-39120 Magdeburg, Germany
[2] SkinSysTecGmbH, Magdeburg, Germany
[3] MelTecGmbH & Co KG, ZENIT Techol, Magdeburg, Germany
关键词
psoriasis; biologics (biologicals); efalizumab (raptiva(TM)); CD11a; proteomics; toponomics; multi-epitope ligand cartography; SEVERE ATOPIC-DERMATITIS; T-CELL MODULATOR; ANTI-CD11A ANTIBODY; MONOCLONAL-ANTIBODY; PERIPHERAL-BLOOD; RANDOMIZED-TRIAL; AUTOIMMUNE LOOP; FLOW-CYTOMETRY; MICROSCOPY; MODERATE;
D O I
10.1159/000104422
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
In a pilot study 6 psoriasis patients were treated over 12 weeks with efalizumab targeting the CD11a subunit of LFA-1. The treatment was well tolerated. Five of these patients proved to be responders with an average decrease in psoriasis area and severity index ( PASI) from 21.3 +/- 5.4 ( day 0) to 3.9 8 +/- 0.6 ( week 12). The nonresponder was subsequently successfully treated with cyclosporin. Skin biopsies were taken before and after efalizumab treatment and subjected to Multi-Epitope Ligand Cartography (MELC) robot microscopy. A MELC library of 46 antibodies including FITC-labeled efalizumab was chosen focusing upon inflammatory epitopes. Quantification of marker expression was performed using a special adaptation to the needs of skin tissue in terms of pixel events normalized to a standardized horizontal skin width of 100 mu m. The before-versus-after comparison for the responders revealed at the 'single epitope level' of MELC analysis a significant decrease ( p < 0.05) in epidermal thickness ( represented by pan-cytokeratin, CD71, CD138), of the expression of common leukocyte antigen (CD45), T-cell markers (CD2, CD4, CD8, CD45R0), CD11a, efalizumab binding site (EfaBS), and CD58. At the 'EfaBS-centered, double colocation level' a corresponding decrease was observed for CD2, CD3, CD4, CD8, CD11a, CD13, CD26, CD44, CD45, CD45R0, D54, CD62L, HLA- DR, and TIA-1. MELC analysis at the 'multicombinatorial level' revealed predominant combinatorial molecular phenotype ( CMP) motifs, which showed an efalizumab treatment-dependent significant decrease. These CMP motifs were defined as toponomic combinations of lead markers for ( i) leukocytes in general ( CD45), (ii) T cells ( CD2, CD3, CD4, CD45R0, CD45RA), (iii) macrophages (CD68), (iv) cell activation ( CD13, CD26, HLA- DR), and ( v) cell adhesion ( CD11a, EfaBS). Thirty-five of the most relevant 50 CMP motifs were directly related to the T-cell type. A descriptive statistical analysis of the nonresponder before treatment showed a below-responder range degree of expression for CD4, CD8, CD44 (H-CAM), CD56, CD62L, HLA-DQ, and also for these epitopes in colocation with EfaBS. In the nonresponder and before treatment we observed an above-responder range degree of expression for CD54 (ICAM-1) as LFA-1 ligand. In conclusion, the topo-proteomic data provide new diversified insights into the pleiotropic cellular dynamics in psoriatic skin lesions under effective efalizumab treatment. Moreover, the data may be relevant to the future development of possible strategies for individual prediction of efalizumab treatment response or nonresponse. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:237 / 252
页数:16
相关论文
共 37 条
  • [1] Interferon-γ-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis:: Exploration of pharmaco- and gene-therapeutic effects
    Böckelmanna, R
    Horn, T
    Gollnick, H
    Bonnekoh, B
    [J]. SKIN PHARMACOLOGY AND PHYSIOLOGY, 2005, 18 (01) : 42 - 54
  • [2] The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by multi-epitope ligand cartography robot technology -: Introduction of a novel biological drug-binding biochip assay
    Bonnekoh, B.
    Boeckelmann, R.
    Pommer, A. J.
    Malykh, Y.
    Philipsen, L.
    Gollnick, H.
    [J]. SKIN PHARMACOLOGY AND PHYSIOLOGY, 2007, 20 (02) : 96 - 111
  • [3] Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy
    Bonnekoh, Bernd
    Malykh, Yanina
    Boeckelmann, Raik
    Bartsch, Sebastian
    Pommer, Ansgar J.
    Gollnick, Harald
    [J]. EUROPEAN JOURNAL OF DERMATOLOGY, 2006, 16 (06) : 623 - 635
  • [4] Bonnekoh B, 2007, J AM ACAD DERMATOL, V56, P162, DOI 10.1016/j.jaad.2006.07.034
  • [5] Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
    Chaudhari, U
    Romano, P
    Mulcahy, LD
    Dooley, LT
    Baker, DG
    Gottlieb, AB
    [J]. LANCET, 2001, 357 (9271) : 1842 - 1847
  • [6] Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections
    Chaurand, P
    Schwartz, SA
    Caprioli, RM
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2002, 6 (05) : 676 - 681
  • [7] Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice
    Coffey, GP
    Fox, JA
    Pippig, S
    Palmieri, S
    Reitz, B
    Gonzales, M
    Bakshi, A
    Padilla-Eagar, J
    Fielder, PJ
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (05) : 623 - 629
  • [8] In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells
    Coffey, GP
    Stefanich, E
    Palmieri, S
    Eckert, R
    Padilla-Eagar, J
    Fielder, PJ
    Pippig, S
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (03) : 896 - 904
  • [9] Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
    Ellis, CN
    Krueger, GG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (04) : 248 - 255
  • [10] Monitoring hyperproliferative disorders in human skin: Flow cytometry of changing cytokeratin expression
    Franssen, MEJ
    Boezeman, JBM
    van de Kerkhof, PCM
    van Erp, PEJ
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2004, 57B (01): : 32 - 39